In fiscal year 2025, Cellromax Science (471820) reported revenue of 22.2 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2025 | 22.2 billion KRW | 2.8 billion KRW | — | [source] |
| 2024 | 21.6 billion KRW | 5.5 billion KRW | — | [source] |
| 2023 | 19.3 billion KRW | 4.6 billion KRW | — | — |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2025 | 51.0 billion KRW | 4.0 billion KRW | 47.0 billion KRW | [source] |
| 2024 | 49.1 billion KRW | 4.6 billion KRW | 44.5 billion KRW | [source] |
| 2023 | — | — | — | — |
Figures for the relevant year were not collected.
Years without a source link are outside the DART financial API collection period.
Balance sheet figures for the relevant year were not collected.